Uptake of Shingrix vaccine in its first year on the National Immunisation Program: an analysis of Australian Immunisation Register data

Shingrix replaced Zostavax on the Australian National Immunisation Program (NIP) for shingles vaccination in 2023. Using Australian Immunisation Register data, we analysed Shingrix uptake over the first year after NIP inclusion: nearly one-third of eligible adults aged ≥65 years received ≥1 dose, substantially increasing shingles vaccination coverage. However, protection among older adults remains suboptimal, with equity gaps. Shingrix’s high effectiveness, safety for immunocompromised people and broader eligibility provide an opportunity to better protect high-risk groups.